Phillip D. Carter at Biopharma Executive
Phillip Carter brings over 20 years of experience building and leading high-performing commercial organizations across several industry-leading biotechnology companies, including GlaxoSmithKline, Alexion, Horizon Therapeutics, and Orchard Therapeutics. He has launched and expanded the adoption of multiple first-in-class and blockbuster products spanning a broad range of therapeutic areas and markets.
Phillip has dedicated more than a decade to commercializing medicines for rare and ultra-rare diseases and is an active member of the Cell & Gene Therapy Community, serving as committee and sub-team member to multiple industry organizations, including Biotechnology Innovation Organization (BIO) and MIT’s FOCUS|NEW Drug Development Paradigms (NEWDIGS) initiative.
Phillip holds a Bachelor’s of Science degree in Management/Marketing from the University of North Carolina at Greensboro and has completed Executive Education programs at The Wharton School at the University of Pennsylvania and The Kellogg School of Management at Northwestern University.